Cagrilintide
Also known as: Cagri, AM833, Cagrilintide acetate
Classification
Peptide
Regulatory Status
Overview
Cagrilintide is a long-acting amylin analogue that engages amylin and calcitonin receptors to reduce energy intake. It has been studied alone and with GLP-1 agonists for weight management but is not an approved drug in this record.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
ClassB source cannot establish canonical regulatory or safety fields. The statements below are retained as uncertainty, not as a label-backed verdict. | Regulatory status: not-established | Contraindication: No approved label; not for unsupervised clinical use. Class GI intolerance risks apply. | Warning: Clinical trials report gastrointestinal adverse events typical of amylin/incretin-pathway agents (nausea, vomiting, constipation/diarrhea patterns). | Warning: Gray-market research peptides labeled cagrilintide are not approved products; sterility and identity are uncertain. | Precaution: Investigational/prescription-development status only; combination use with GLP-1 agents is a trial construct, not consumer guidance. | Adverse effect: nausea | Adverse effect: vomiting | Adverse effect: gastrointestinal intolerance | Serious adverse effect: severe GI adverse events; full long-term safety label not established pending approval
Pathways
Interactions & cautions
Drug interactions
GLP-1 receptor agonists and other incretin/amylin agents — Additive GI adverse effects expected; combination regimens belong in controlled clinical contexts. (high)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.